Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

cholesterol-rewritten:-verve’s-base-editing-therapy-may-disrupt-a-$20b-market

High cholesterol has long been a silent threat lurking in the bloodstream. For millions of people, especially those with familial hypercholesterolemia, keeping “bad” LDL cholesterol in check means a lifetime of daily statin pills or frequent injections. Yet many patients still don’t hit their target LDL levels – whether due to medication adherence challenges or stubborn genetics. This leaves them at elevated risk of heart attacks and strokes, despite existing therapies. But what if a single treatment could permanently lower your cholesterol, freeing you from the treadmill of continuous medication?

That futuristic scenario is edging closer to reality.

 » Read More

Read Next
Scroll to Top